{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:34:00Z","timestamp":1793136840886,"version":"4.5.0"},"reference-count":117,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,9,2]]},"abstract":"<jats:sec id=\"ab-jrv250017-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Up to 40% of men older than 50 years have lower urinary tract symptoms, including urinary urgency, nocturia, and weak urinary stream, due to disorders of the bladder and prostate. These symptoms negatively affect quality of life and may be associated with urinary retention, which can cause kidney insufficiency, bladder calculi, hematuria, and urinary tract infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250017-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      In men, lower urinary tract symptoms can be caused by bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH), an overactive bladder detrusor (a syndrome of urinary urgency and frequency), or both. Behavioral therapy, including pelvic floor physical therapy, timed voiding (voiding at specific intervals), and fluid restriction, can improve symptoms. Medications including \u03b1-blockers (such as tamsulosin), 5\u03b1-reductase inhibitors (such as finasteride), and phosphodiesterase 5 inhibitors (such as tadalafil) improve lower urinary tract symptoms (mean improvement, 3-10 points on the International Prostate Symptom Score [IPSS], which ranges from 0-35, with higher scores indicating greater severity) and can prevent symptom worsening measured by increased IPSS greater than or equal to 4 points or development of secondary sequelae, such as urinary retention. Combination therapies are more effective than monotherapy. For example, \u03b1-blockade (eg, tamsulosin) combined with 5\u03b1-reductase inhibition (eg, finasteride) lowers progression risk to less than 10% compared with 10% to 15% with monotherapy. Treatment for overactive bladder detrusor muscle, including anticholinergics (eg, trospium) and \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      agonists (eg, mirabegron), reduces voiding frequency by 2 to 4 times per day and reduces episodes of urinary incontinence by 10 to 20 times per week. Surgery (eg, transurethral resection of the prostate, holmium laser enucleation of the prostate) and minimally invasive surgery are highly effective for refractory or complicated cases of BPH, defined as persistent symptoms despite behavioral and pharmacologic therapy, and these therapies can improve IPSS by 10 to 15 points. Minimally invasive procedures, such as water vapor therapy (endoscopic injection of steam into BPH tissue) and prostatic urethral lift (endoscopic insertion of nonabsorbable suture implants that mechanically open the urethra), have lower complication rates of incontinence (0%-8%), erectile dysfunction (0%-3%), and retrograde ejaculation (0%-3%) but are associated with increased need for surgical retreatment (3.4%-21%) compared with transurethral resection of the prostate (5%) and holmium laser enucleation of the prostate (3.3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250017-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>\n                      Lower urinary tract symptoms, defined as urinary urgency, nocturia, or weak stream, are common among men and are usually caused by BPH, overactive bladder detrusor, or both. First-line therapy consists of behavioral interventions, such as pelvic floor physical therapy and timed voiding, as well as pharmacologic therapy, including \u03b1-adrenergic blockers (tamsulosin), 5\u03b1-reductase inhibitors (finasteride), phosphodiesterase inhibitors (tadalafil), anticholinergics (trospium), and \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      agonists (mirabegron).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.7045","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:00:37Z","timestamp":1752505237000},"page":"809","source":"Crossref","is-referenced-by-count":93,"title":["Lower Urinary Tract Symptoms in Men"],"prefix":"10.1001","volume":"334","author":[{"given":"John T.","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey A.","family":"Dauw","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey N.","family":"Brodsky","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"jrv250017r1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"jrv250017r2","doi-asserted-by":"publisher","first-page":"19819","DOI":"10.1038\/s41598-020-76846-0","article-title":"Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland: an Eastern European study.","volume":"10","author":"Przydacz","year":"2020","journal-title":"Sci Rep"},{"issue":"34","key":"jrv250017r3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011554","article-title":"Epidemiology of lower urinary tract symptoms in a cross-sectional, population-based study: the status in China.","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"jrv250017r4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-5347(17)35405-8","article-title":"The prevalence of prostatism: a population-based survey of urinary symptoms.","volume":"150","author":"Chute","year":"1993","journal-title":"J Urol"},{"issue":"9","key":"jrv250017r5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/j.1742-1241.2007.01508.x","article-title":"Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.","volume":"61","author":"Naslund","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"2","key":"jrv250017r7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","article-title":"Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms.","volume":"84","author":"Gravas","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"jrv250017r8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I\u2014initial work-up and medical management.","volume":"206","author":"Lerner","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"jrv250017r9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/JU.0000000000002184","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II\u2014surgical evaluation and treatment.","volume":"206","author":"Lerner","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"jrv250017r10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023.","volume":"211","author":"Sandhu","year":"2024","journal-title":"J Urol"},{"issue":"6","key":"jrv250017r12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/j.1939-4640.1991.tb00272.x","article-title":"The pathophysiology of benign prostatic hyperplasia.","volume":"12","author":"McConnell","year":"1991","journal-title":"J Androl"},{"issue":"5","key":"jrv250017r13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000496289","article-title":"Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review.","volume":"65","author":"Madersbacher","year":"2019","journal-title":"Gerontology"},{"issue":"2","key":"jrv250017r14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pop.2019.02.003","article-title":"Benign prostatic hyperplasia.","volume":"46","author":"Langan","year":"2019","journal-title":"Prim Care"},{"issue":"6","key":"jrv250017r15","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment.","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"jrv250017r16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11884-023-00690-x","article-title":"Pathophysiological mechanisms involved in overactive bladder\/detrusor overactivity.","volume":"18","author":"Chess-Williams","year":"2023","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"4","key":"jrv250017r17","doi-asserted-by":"publisher","DOI":"10.1177\/15579883211036786","article-title":"Global, regional, and national incidence and year lived with disability for benign prostatic hyperplasia from 1990 to 2019.","volume":"15","author":"Xu","year":"2021","journal-title":"Am J Mens Health"},{"issue":"11","key":"jrv250017r18","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","article-title":"The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease study 2019.","volume":"3","author":"GBD 2019 Benign Prostatic Hyperplasia Collaborators","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"jrv250017r20","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"issue":"6","key":"jrv250017r21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States.","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"issue":"5","key":"jrv250017r22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age.","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"jrv250017r23","doi-asserted-by":"publisher","DOI":"10.1177\/2377960818811773","article-title":"Prevalence, burden, and treatment of lower urinary tract symptoms in men aged 50 and older: a systematic review of the literature.","volume":"4","author":"Zhang","year":"2018","journal-title":"SAGE Open Nurs"},{"issue":"4","key":"jrv250017r24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.ede.0000219723.14476.28","article-title":"Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins.","volume":"17","author":"Rohrmann","year":"2006","journal-title":"Epidemiology"},{"issue":"2","key":"jrv250017r25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrurol.2015.301","article-title":"Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.","volume":"13","author":"Vignozzi","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"4","key":"jrv250017r26","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.juro.2006.11.065","article-title":"Race\/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.","volume":"177","author":"Kristal","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"jrv250017r27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/JU.0000000000003077","article-title":"Role of antimuscarinics combined with alpha-blockers in the management of urinary storage symptoms in patients with benign prostatic hyperplasia: an updated systematic review and meta-analysis.","volume":"209","author":"Lenfant","year":"2023","journal-title":"J Urol"},{"issue":"3","key":"jrv250017r28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJMcp1106637","article-title":"Clinical practice: benign prostatic hyperplasia and lower urinary tract symptoms.","volume":"367","author":"Sarma","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv250017r29","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/nau.25000","article-title":"Treatment of overactive bladder in men: is it really different?","volume":"41","author":"Shapiro","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"jrv250017r30","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia.","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"issue":"1","key":"jrv250017r31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/JU.0000000000000465","article-title":"A new brief clinical assessment of lower urinary tract symptoms for women and men: LURN SI-10.","volume":"203","author":"Cella","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"jrv250017r32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.juro.2017.01.075","article-title":"AUA white paper on nonneurogenic chronic urinary retention: consensus definition, treatment algorithm, and outcome end points.","volume":"198","author":"Stoffel","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"jrv250017r33","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.juro.2017.04.097","article-title":"Evidence of the impact of diet, fluid intake, caffeine, alcohol and tobacco on lower urinary tract symptoms: a systematic review.","volume":"198","author":"Bradley","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"jrv250017r34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019.","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"issue":"7583","key":"jrv250017r35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/bmj.39010.551319.AE","article-title":"Self management for men with lower urinary tract symptoms: randomised controlled trial.","volume":"334","author":"Brown","year":"2007","journal-title":"BMJ"},{"issue":"3","key":"jrv250017r36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamainternmed.2019.6398","article-title":"Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial.","volume":"180","author":"Burgio","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"jrv250017r37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1370\/afm.2609","article-title":"Self-management for men with lower urinary tract symptoms: a systematic review and meta-analysis.","volume":"19","author":"Albarqouni","year":"2021","journal-title":"Ann Fam Med"},{"key":"jrv250017r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2024.105742","article-title":"Self-management interventions for men with lower urinary tract symptoms: a systematic review and meta-analysis of randomized controlled trials.","volume":"131","author":"Kumar","year":"2025","journal-title":"Arch Gerontol Geriatr"},{"issue":"13","key":"jrv250017r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/GVBC3182","article-title":"Lower urinary tract symptoms in men: the TRIUMPH cluster RCT.","volume":"28","author":"Worthington","year":"2024","journal-title":"Health Technol Assess"},{"issue":"12","key":"jrv250017r40","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/j.1532-5415.2011.03724.x","article-title":"Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) trial.","volume":"59","author":"Burgio","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"jrv250017r41","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3892\/mmr.2014.2646","article-title":"Caffeine enhances micturition through neuronal activation in micturition centers.","volume":"10","author":"Cho","year":"2014","journal-title":"Mol Med Rep"},{"issue":"5","key":"jrv250017r42","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/nau.24344","article-title":"What do we really know about the role of caffeine on urinary tract symptoms? a scoping review on caffeine consumption and lower urinary tract symptoms in adults.","volume":"39","author":"Le Berre","year":"2020","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"jrv250017r43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.eururo.2015.12.034","article-title":"a1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies.","volume":"69","author":"Fusco","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"jrv250017r44","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1002\/nau.23554","article-title":"Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: a systematic review and meta-analysis of urodynamic studies.","volume":"37","author":"Fusco","year":"2018","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"jrv250017r45","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0022-5347(17)50110-X","article-title":"Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia.","volume":"132","author":"Lepor","year":"1984","journal-title":"J Urol"},{"issue":"11","key":"jrv250017r46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030405","article-title":"Discontinuation of alpha-blocker therapy in men with lower urinary tract symptoms: a systematic review and meta-analysis.","volume":"9","author":"van der Worp","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"jrv250017r47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/ICU.0000000000000815","article-title":"Dealing with floppy iris syndrome.","volume":"33","author":"Park","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"jrv250017r48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0090-4295(01)01347-4","article-title":"5Alpha-reductase inhibitors: what role should they play?","volume":"58","author":"Kaplan","year":"2001","journal-title":"Urology"},{"issue":"11","key":"jrv250017r49","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/jnci\/djy036","article-title":"Risk of prostate cancer in men treated with 5a-reductase inhibitors\u2014a large population-based prospective study.","volume":"110","author":"Wallerstedt","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"jrv250017r50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1940-6207.CAPR-08-0092","article-title":"Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.","volume":"1","author":"Redman","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"issue":"8","key":"jrv250017r51","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14656566.2019.1589452","article-title":"Tadalafil for the treatment of benign prostatic hyperplasia.","volume":"20","author":"M\u00f3nica","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"jrv250017r52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.eururo.2009.04.033","article-title":"Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.","volume":"56","author":"Porst","year":"2009","journal-title":"Eur Urol"},{"issue":"4","key":"jrv250017r53","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.juro.2008.06.079","article-title":"Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.","volume":"180","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"issue":"3","key":"jrv250017r54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/luts.12242","article-title":"Effect of tadalafil add-on therapy in patients with persistant [sic] storage symptoms refractory to a1-adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: a randomized pilot trial comparing tadalafil and solifenacin.","volume":"11","author":"Urakami","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"jrv250017r55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00345-018-2370-z","article-title":"Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.","volume":"37","author":"Zhang","year":"2019","journal-title":"World J Urol"},{"key":"jrv250017r56","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9298483","article-title":"Discontinuation rates of tadalafil alone and in combination with a-blockers in the treatment of male lower urinary tract symptoms with or without coexisting erectile dysfunction: a systematic review and meta-analysis.","volume":"2022","author":"Chen","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"5","key":"jrv250017r57","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/bju.14849","article-title":"Effect of tadalafil 5 mg on post-micturition dribble in men with lower urinary tract symptoms: a multicentre, double-blind, randomized, placebo-controlled trial.","volume":"124","author":"Yang","year":"2019","journal-title":"BJU Int"},{"issue":"6","key":"jrv250017r58","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ageing\/afaa090","article-title":"Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis.","volume":"49","author":"Pieper","year":"2020","journal-title":"Age Ageing"},{"issue":"8","key":"jrv250017r59","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/nau.25037","article-title":"SUFU white paper on overactive bladder anticholinergic medications and dementia risk.","volume":"41","author":"Zillioux","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"jrv250017r60","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/JU.0000000000002804","article-title":"Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the French national medical-administrative database.","volume":"208","author":"Malcher","year":"2022","journal-title":"J Urol"},{"issue":"8","key":"jrv250017r61","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study.","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"11","key":"jrv250017r62","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","article-title":"The cognitive effect of anticholinergics for patients with overactive bladder.","volume":"18","author":"Welk","year":"2021","journal-title":"Nat Rev Urol"},{"key":"jrv250017r63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.euros.2022.10.008","article-title":"The impact of anticholinergic use for overactive bladder on cognitive changes in adults with normal cognition, mild cognitive impairment, or dementia.","volume":"46","author":"Welk","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"jrv250017r64","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.juro.2013.05.058","article-title":"The efficacy and safety of combined therapy with a-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis.","volume":"190","author":"Filson","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"jrv250017r65","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12894-023-01327-1","article-title":"Comparison of add-on medications for persistent storage symptoms after a-blocker treatment in BPH patients\u2014a network meta-analysis.","volume":"23","author":"Su","year":"2023","journal-title":"BMC Urol"},{"issue":"1","key":"jrv250017r66","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/nau.23852","article-title":"Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.","volume":"38","author":"Shin","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"jrv250017r67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000003999","article-title":"Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial.","volume":"212","author":"Staskin","year":"2024","journal-title":"J Urol"},{"issue":"8","key":"jrv250017r68","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/nau.25532","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder.","volume":"43","author":"Cameron","year":"2024","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"jrv250017r69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/luts.12243","article-title":"A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).","volume":"11","author":"Yamanishi","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"jrv250017r70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12894-019-0446-8","article-title":"Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.","volume":"19","author":"Zhou","year":"2019","journal-title":"BMC Urol"},{"issue":"5","key":"jrv250017r71","doi-asserted-by":"publisher","DOI":"10.1177\/1557988319882597","article-title":"Meta-analysis of efficacy and safety of tadalafil plus tamsulosin compared with tadalafil alone in treating men with benign prostatic hyperplasia and erectile dysfunction.","volume":"13","author":"Zhou","year":"2019","journal-title":"Am J Mens Health"},{"issue":"5","key":"jrv250017r72","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/bju.15027","article-title":"Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial.","volume":"125","author":"Nagasubramanian","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"jrv250017r73","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH).","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"2","key":"jrv250017r74","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/nau.24285","article-title":"A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT study).","volume":"39","author":"Yamanishi","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"jrv250017r75","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.urology.2020.09.040","article-title":"Mirabegron vs placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a safety analysis from the randomized, phase 4 PLUS study.","volume":"147","author":"Herschorn","year":"2021","journal-title":"Urology"},{"issue":"4","key":"jrv250017r76","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/pros.24663","article-title":"A prospective, randomized, open-label, parallel trial comparing the efficacy of a-blocker or 5a-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.","volume":"84","author":"Lee","year":"2024","journal-title":"Prostate"},{"key":"jrv250017r77","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1287212","article-title":"Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review.","volume":"14","author":"He","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"jrv250017r78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/biomedicines12010110","article-title":"Evaluating the impact of benign prostatic hyperplasia surgical treatments on sexual health.","volume":"12","author":"Kaltsas","year":"2024","journal-title":"Biomedicines"},{"issue":"12","key":"jrv250017r79","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11934-020-01012-y","article-title":"A systematic review of reported ejaculatory dysfunction in clinical trials evaluating minimally invasive treatment modalities for BPH.","volume":"21","author":"Lokeshwar","year":"2020","journal-title":"Curr Urol Rep"},{"issue":"3","key":"jrv250017r80","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eururo.2010.06.005","article-title":"Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.","volume":"58","author":"Ahyai","year":"2010","journal-title":"Eur Urol"},{"issue":"4","key":"jrv250017r81","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41391-019-0135-4","article-title":"Efficacy and safety of enucleation vs resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials.","volume":"22","author":"Zhang","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"jrv250017r82","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.juro.2011.06.065","article-title":"Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup [sic].","volume":"186","author":"Elmansy","year":"2011","journal-title":"J Urol"},{"issue":"6","key":"jrv250017r83","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1111\/andr.12887","article-title":"Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP)\u2014impact on sexual function and evaluation of patient bother using validated questionnaires.","volume":"8","author":"Gild","year":"2020","journal-title":"Andrology"},{"issue":"3","key":"jrv250017r84","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41391-022-00616-4","article-title":"Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases.","volume":"26","author":"Pandolfo","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"jrv250017r85","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11701-022-01460-3","article-title":"Laparoscopic simple prostatectomy versus robot-assisted simple prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of comparative trials.","volume":"17","author":"Li","year":"2023","journal-title":"J Robot Surg"},{"issue":"1","key":"jrv250017r86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/pcan.2013.52","article-title":"Robotic-assisted simple prostatectomy: a systematic review and report of a single institution case series.","volume":"17","author":"Banapour","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"jrv250017r87","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.urology.2004.03.033","article-title":"Long-term results of open transvesical prostatectomy from a contemporary series of patients.","volume":"64","author":"Varkarakis","year":"2004","journal-title":"Urology"},{"issue":"1","key":"jrv250017r88","first-page":"10960","article-title":"Five-year outcomes for aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH.","volume":"29","author":"Gilling","year":"2022","journal-title":"Can J Urol"},{"key":"jrv250017r89","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.urology.2018.12.002","article-title":"Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes.","volume":"125","author":"Gilling","year":"2019","journal-title":"Urology"},{"issue":"1","key":"jrv250017r90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00345-009-0496-8","article-title":"The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials.","volume":"28","author":"Lourenco","year":"2010","journal-title":"World J Urol"},{"issue":"1","key":"jrv250017r91","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.afju.2012.04.007","article-title":"Transurethral incision versus transurethral resection of the prostate in small prostatic adenoma: long-term follow-up.","volume":"18","author":"Abd-El Kader","year":"2012","journal-title":"Afr J Urol"},{"issue":"1","key":"jrv250017r92","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.eururo.2015.07.054","article-title":"A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study.","volume":"69","author":"Thomas","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"jrv250017r93","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/luts.12435","article-title":"Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.","volume":"14","author":"Babar","year":"2022","journal-title":"Low Urin Tract Symptoms"},{"key":"jrv250017r94","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","article-title":"Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study.","volume":"126","author":"McVary","year":"2019","journal-title":"Urology"},{"key":"jrv250017r95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.euros.2020.05.001","article-title":"A systematic review and meta-analysis of prostatic urethral lift for male lower urinary tract symptoms secondary to benign prostatic hyperplasia.","volume":"19","author":"Xiang","year":"2020","journal-title":"Eur Urol Open Sci"},{"key":"jrv250017r96","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.urology.2020.12.022","article-title":"The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial.","volume":"153","author":"Chughtai","year":"2021","journal-title":"Urology"},{"issue":"12","key":"jrv250017r97","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00345-020-03140-z","article-title":"Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02 study.","volume":"38","author":"Kadner","year":"2020","journal-title":"World J Urol"},{"issue":"1","key":"jrv250017r98","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bju.14141","article-title":"3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction.","volume":"122","author":"Porpiglia","year":"2018","journal-title":"BJU Int"},{"issue":"1","key":"jrv250017r99","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00330-018-5564-2","article-title":"Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis.","volume":"29","author":"Malling","year":"2019","journal-title":"Eur Radiol"},{"issue":"1","key":"jrv250017r100","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12894-023-01397-1","article-title":"Comparing prostatic artery embolization to surgical and minimally invasive procedures for the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis.","volume":"24","author":"Altman","year":"2024","journal-title":"BMC Urol"},{"issue":"5","key":"jrv250017r101","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.euf.2023.03.004","article-title":"Pharmacologic and surgical retreatment after office-based treatments for benign prostatic hyperplasia: a systematic review.","volume":"9","author":"Baboudjian","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"6","key":"jrv250017r102","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.euf.2022.06.007","article-title":"Impact of surgery for benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis of erectile function and ejaculatory function.","volume":"8","author":"Manfredi","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"6","key":"jrv250017r103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0090-4295(01)01298-5","article-title":"Natural history of benign prostatic hyperplasia.","volume":"58","author":"Jacobsen","year":"2001","journal-title":"Urology"},{"issue":"2","key":"jrv250017r104","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.juro.2012.03.125","article-title":"Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men.","volume":"188","author":"Platz","year":"2012","journal-title":"J Urol"},{"issue":"1","key":"jrv250017r105","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0022-5347(01)63011-8","article-title":"5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study.","volume":"160","author":"Flanigan","year":"1998","journal-title":"J Urol"},{"issue":"6","key":"jrv250017r106","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.urology.2004.08.049","article-title":"Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years.","volume":"64","author":"Djavan","year":"2004","journal-title":"Urology"},{"key":"jrv250017r107","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","article-title":"BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.","volume":"101","author":"Roehrborn","year":"2008","journal-title":"BJU Int"},{"issue":"2","key":"jrv250017r108","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0022-5347(01)64508-7","article-title":"Natural history of prostatism: risk factors for acute urinary retention.","volume":"158","author":"Jacobsen","year":"1997","journal-title":"J Urol"},{"issue":"25","key":"jrv250017r109","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250017r110","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1464-410X.2006.06110.x","article-title":"Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"issue":"4","key":"jrv250017r111","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0090-4295(99)00232-0","article-title":"Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo.","volume":"54","author":"Roehrborn","year":"1999","journal-title":"Urology"},{"issue":"1","key":"jrv250017r112","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"issue":"7","key":"jrv250017r113","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/j.1742-1241.2008.01785.x","article-title":"Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.","volume":"62","author":"Emberton","year":"2008","journal-title":"Int J Clin Pract"},{"key":"jrv250017r114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000052592","article-title":"Long-term effects on BPH of medical and instrumental therapies.","volume":"39","author":"Puppo","year":"2001","journal-title":"Eur Urol"},{"issue":"6","key":"jrv250017r115","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2005.12.072","article-title":"Techniques and long-term results of surgical procedures for BPH.","volume":"49","author":"Reich","year":"2006","journal-title":"Eur Urol"},{"key":"jrv250017r116","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.urology.2021.04.019","article-title":"Comparison of long-term effect and complications between holmium laser enucleation and transurethral resection of prostate: Nations-Wide Health Insurance study.","volume":"154","author":"Kim","year":"2021","journal-title":"Urology"},{"issue":"1","key":"jrv250017r117","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"key":"jrv250017r6","volume-title":"Urologic Diseases in America: Annual Data Report 2024","author":"National Institutes of Health","year":"2024"},{"key":"jrv250017r11","author":"Washington","year":"2020"},{"key":"jrv250017r19","volume-title":"Urologic Diseases in America: Annual Data Report","author":"Urologic Diseases in America","year":"2023"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2836455\/jama_wei_2025_rv_250017_1755795632.37185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:00:57Z","timestamp":1756825257000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2836455"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":117,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.7045","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}